RE: HCI Selling Complete7 Dec 2023 14:58
As I remember, they talked about the possibility of more frequent dosing during Science Day. If not that, then I did in direct communication with Andrew Saunders after Science Day, so you may have me to thank for the idea - that was a joke for the hard of bantering.
I should think, Bella, that more frequent dosing is an obvious development when MTD is so elusive since it provides data for more the choice about a RP2D regimen, from both a safety and an efficacy point of view, as well as having shorter cycles and therefore more cohorts within a fixed time. Who really proposed it? Does it matter? It could have been the FDA as likely as Avacta or ANother.
My understandong is that Avacta intends to take AVA6000 through to the clinic for STS (the specific subtypes chosen for Phase 2 if Phase 2 is a pivotal study) but will need to find partner(s) to get it into patients (production, marketting, sales and distribution) globally as all that is beyond the capability of a small biopharma company until the money starts flowing in. Also that partners will be sought to take AVA6000 through to the market for other indications as those will require a lot of trials as there will be combination therapies to compare to standards of care that are with and without doxorubicin/anthracyclines.